# AngioDynamics, Inc. (ANGO) Stock Analysis: Exploring a 59.92% Potential Upside

- Link: https://www.directorstalkinterviews.com/angiodynamics-inc-ango-stock-analysis-exploring-a-59-92-potential-upside/4121268632
- Published: 2026-10-30T11:15:43+00:00
- Author: Madison Wilson

AngioDynamics, Inc. (ANGO), a key player in the healthcare sector, specifically 
within the medical instruments and supplies industry, has been capturing attention
with a notable potential upside of nearly 60%. This intriguing figure is bolstered
by a strong consensus of buy ratings from analysts, making the company an attractive
consideration for investors seeking opportunities in the medical technology landscape.

With a current market capitalization of $519.37 million, AngioDynamics operates 
through two primary segments—Med Tech and Med Device—offering a diversified portfolio
of products. Among its innovative offerings are the Auryon Atherectomy system and
the AlphaVac mechanical thrombectomy system, both designed to address significant
medical needs in cardiovascular disease and cancer treatment. The company’s commitment
to advancing medical technology is further exemplified by its NanoKnife IRE Ablation
System and a robust range of peripheral products that support various invasive procedures.

Despite its promising product lineup, AngioDynamics currently faces financial challenges,
as indicated by a negative EPS of -0.78 and a return on equity of -19.22%. These
figures suggest that the company is still navigating hurdles on its path to profitability.
However, the firm’s positive revenue growth of 6.90% and a solid free cash flow 
of over $21 million highlight its potential to overcome these obstacles and achieve
a stronger financial footing.

The stock, currently priced at $12.35, sits near the lower end of its 52-week range
of $9.70 to $16.13. This positioning, coupled with a 50-day moving average of $14.26
and a 200-day moving average of $12.47, may signal a buying opportunity for investors
looking to capitalize on the stock’s potential rebound. Despite a relative strength
index (RSI) of 44.92, which does not indicate an overbought or oversold condition,
the technical indicators suggest cautious optimism.

Analysts have set a target price range for AngioDynamics between $17.00 and $24.00,
with an average target of $19.75, reflecting a consensus belief in the company’s
growth prospects. The absence of sell ratings further underscores the positive sentiment
surrounding the stock. However, investors should weigh these optimistic targets 
against the company’s current lack of profitability and negative forward P/E ratio
of -108.97.

For dividend-seeking investors, AngioDynamics offers no yield, as it currently does
not distribute dividends. This factor, combined with a payout ratio of 0.00%, suggests
that the company is reinvesting earnings back into the business to fuel growth and
development.

AngioDynamics’ focus on cutting-edge medical technology, combined with a promising
analyst outlook, positions it as a compelling choice for investors who are comfortable
with the associated risks. The company’s ability to leverage its innovative products
to drive revenue growth while managing its financial challenges will be crucial 
in realizing the substantial upside potential that analysts predict. As the healthcare
sector continues to evolve, AngioDynamics remains a stock to watch for those seeking
dynamic growth opportunities within the medical technology arena.

Share on:
